How is Pfizer's drug different from Wegovy and Mounjaro?

Pfizer's drug is expected to be long-acting, requiring less frequent dosing, but details are not yet disclosed.

When will Pfizer's weight-loss drug launch?

No launch date has been announced yet.

What are the risks of Pfizer investing in the GLP-1 market?

Competition is intense with Eli Lilly and Novo Nordisk dominating, and Pfizer may face regulatory and pricing challenges.

Pfizer Eyes Weight-Loss Market with Long-Acting GLP-1 Drug

After lagging in the GLP-1 race, Pfizer is planning a long-acting weight-loss drug that could reshape its competitive position in the multi-billion dollar obesity market.

July 11, 2026

2 min read

Source: Motley Fool

Pfizer (NYSE: PFE) is planning to launch a long-acting weight-loss drug, aiming to catch up with rivals Eli Lilly (NYSE: LLY) and Novo Nordisk in the growing GLP-1 market. According to a report from Motley Fool, this drug could be Pfizer's best chance to replicate the success of its former blockbuster Lipitor.

The Product

Pfizer has not yet disclosed the drug's name or final details, but it is expected to be a long-acting version of GLP-1 inhibitors, allowing less frequent dosing compared to current products.

Pricing and Availability

Pricing and launch timeline have not been announced. Pfizer may face pricing pressure competing with established drugs like Wegovy and Mounjaro.

Competition

Eli Lilly and Novo Nordisk dominate the GLP-1 market, but Pfizer hopes to differentiate with less frequent dosing. Competition remains intense as multiple companies advance similar candidates.

Potential Impact on Pfizer

If successful, the drug could significantly boost Pfizer's revenue and offset declines in other products. However, risks are high given the company's late entry into the race.

Frequently Asked Questions

GLP-1 drugs mimic a natural hormone that regulates blood sugar and appetite, used for type 2 diabetes and weight loss.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.